We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
-16.73%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$300M
AUM Growth
-$39.4M
(-12%)
Cap. Flow
+$19.1M
Cap. Flow
% of AUM
6.37%
Top 10 Holdings %
Top 10 Hldgs %
40.88%
Holding
110
New
17
Increased
29
Reduced
31
Closed
33
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$15.1M |
| 2 |
AET
Aetna Inc
AET
|
+$9.05M |
| 3 |
Standard BioTools
LAB
|
+$7.23M |
| 4 |
SPNC
Spectranetics Corp
SPNC
|
+$6.43M |
| 5 |
STJ
St Jude Medical
STJ
|
+$5.86M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Labcorp
LH
|
+$9.99M |
| 2 |
BCR
CR Bard Inc.
BCR
|
+$9.92M |
| 3 |
Elevance Health
ELV
|
+$6.68M |
| 4 |
WBA
Walgreens Boots Alliance
WBA
|
+$6.22M |
| 5 |
Intuitive Surgical
ISRG
|
+$4.21M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.86% |
| 2 | Financials | 3.68% |
| 3 | Industrials | 1.11% |
| 4 | Technology | 1.01% |
| 5 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
STJ
1
DELISTED
St Jude Medical
STJ
| $15.5M | 5.17% |
245,526
+82,112
| +50% | +$5.86M |
|
2
Thermo Fisher Scientific
TMO
$213B
| $14.9M | 4.96% |
121,574
+12,624
| +12% | +$1.64M |
|
3
Becton Dickinson
BDX
$45.6B
| $14.3M | 4.76% |
110,180
-27,027
| -20% | -$3.77M |
|
4
Teva Pharmaceuticals
TEVA
$40.8B
| $13.2M | 4.39% |
233,100
+44,300
| +23% | +$2.87M |
|
|
AGN
5
DELISTED
Allergan plc
AGN
| $12.4M | 4.14% |
45,566
-12,600
| -22% | -$3.87M |
|
6
Merck
MRK
$322B
| $11.9M | 3.96% |
251,944
+39,928
| +19% | +$2.12M |
|
|
AET
7
DELISTED
Aetna Inc
AET
| $11M | 3.68% |
100,850
+78,300
| +347% | +$9.05M |
|
|
MNK
8
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $10.2M | 3.39% |
159,009
+152,700
| +2,420% | +$15.1M |
|
9
UnitedHealth
UNH
$376B
| $9.84M | 3.28% |
84,800
+4,400
| +5% | +$527K |
|
10
Globus Medical
GMED
$10.7B
| $9.37M | 3.13% |
453,729
-91,110
| -17% | -$2.31M |
|
11
Stryker
SYK
$125B
| $8.5M | 2.84% |
90,286
+38,847
| +76% | +$3.85M |
|
12
HCA Healthcare
HCA
$87.2B
| $8.05M | 2.69% |
104,025
+35,930
| +53% | +$3.18M |
|
13
Universal Health Services
UHS
$10.2B
| $7.17M | 2.39% |
57,475
-21,100
| -27% | -$2.94M |
|
14
Medtronic
MDT
$109B
| $6.98M | 2.33% |
104,318
-21,644
| -17% | -$1.59M |
|
|
SPNC
15
DELISTED
Spectranetics Corp
SPNC
| $6.64M | 2.22% |
563,650
+359,100
| +176% | +$6.43M |
|
|
ESRX
16
DELISTED
Express Scripts Holding Company
ESRX
| $6.17M | 2.06% |
76,187
+29,487
| +63% | +$2.57M |
|
17
Johnson & Johnson
JNJ
$618B
| $5.59M | 1.87% |
59,900
-18,700
| -24% | -$1.81M |
|
|
ALR
18
DELISTED
AlerisLife Inc
ALR
| $4.97M | 1.66% |
160,802
+71,467
| +80% | +$2.71M |
|
|
NVRO
19
DELISTED
NEVRO CORP.
NVRO
| $4.88M | 1.63% |
105,300
+90,800
| +626% | +$4.4M |
|
|
BXLT
20
DELISTED
BAXALTA INC COM STK (DE)
BXLT
| $4.72M | 1.57% |
+149,700
| New | +$5.17M |
|
21
Abbott
ABT
$183B
| $4.69M | 1.57% |
116,605
+94,255
| +422% | +$4.44M |
|
22
Encompass Health
EHC
$11B
| $4.65M | 1.55% |
+152,474
| New | +$5.31M |
|
23
Centene
CNC
$30.7B
| $4.41M | 1.47% |
+162,728
| New | +$5.45M |
|
24
Viatris
VTRS
$20.4B
| $4.35M | 1.45% |
108,100
+76,000
| +237% | +$4.24M |
|
25
Boston Scientific
BSX
$69.5B
| $4.18M | 1.4% |
254,700
+109,600
| +76% | +$1.87M |
|
Similar funds
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
HSCU
Endurant Capital Management's Q3 2015 Portfolio in Review
As of Q3 2015, Endurant Capital Management held 110 positions worth $300M, down 12% from $339M the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Endurant Capital Management deployed $19.1M of net new capital in Q3 2015, opening 17 new positions and adding to 29 existing holdings. Its largest new stake was AMAG Pharmaceuticals: 94,100 shares worth $3.74M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 90% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Labcorp, an estimated $9.99M trimmed.
- Endurant Capital Management's largest Q3 2015 buy was AMAG Pharmaceuticals: 94,100 shares worth $3.74M.
- Endurant Capital Management added most to MALLINCKRODT PUBLIC LIMITED COMPANY in Q3 2015, an estimated $15.1M increase.
- Endurant Capital Management's biggest Q3 2015 reduction was Labcorp, cutting an estimated $9.99M.
- Endurant Capital Management fully exited Elevance Health in Q3 2015, selling an estimated $6.68M.
- Endurant Capital Management's ten largest holdings make up 41% of its $300M portfolio in Q3 2015.
- Endurant Capital Management opened 17 new positions and closed 33 in Q3 2015.
- Endurant Capital Management's portfolio value fell 12% quarter-over-quarter to $300M.
Based on Endurant Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.